COVID-19 lung disease shares driver AT2 cytopathic features with Idiopathic pulmonary fibrosis
Open Access
- 20 July 2022
- journal article
- research article
- Published by Elsevier in EBioMedicine
- Vol. 82, 104185
Abstract
No abstract availableKeywords
All Related Versions
Funding Information
- American Association of Immunologists (U19AI142742)
- National Institutes of Health (R01-AI155696)
- National Institutes of Health (R01DK107585)
- National Institutes of Health (CA100768)
- National Institutes of Health (R01-GM138385)
- National Institutes of Health (R01-AI141630)
- National Institutes of Health (R00-CA151673)
- National Institutes of Health (CA160911)
This publication has 129 references indexed in Scilit:
- Type 2 alveolar cells are stem cells in adult lungJournal of Clinical Investigation, 2013
- Multiple stromal populations contribute to pulmonary fibrosis without evidence for epithelial to mesenchymal transitionProceedings of the National Academy of Sciences, 2011
- Bayesian probit regression model for the diagnosis of pulmonary fibrosis: proof-of-principleBMC Medical Genomics, 2011
- Quantification of Collagen Organization and Extracellular Matrix Factors within the Healing LigamentMicroscopy and Microanalysis, 2011
- MiDReG: A method of mining developmentally regulated genes using Boolean implicationsProceedings of the National Academy of Sciences, 2010
- Ly6d marks the earliest stage of B-cell specification and identifies the branchpoint between B-cell and T-cell developmentGenes & Development, 2009
- Boolean implication networks derived from large scale, whole genome microarray datasetsGenome Biology, 2008
- Serum IL-15 in patients with early systemic sclerosis: a potential novel marker of lung diseaseArthritis Research & Therapy, 2007
- Extracting binary signals from microarray time-course dataNucleic Acids Research, 2007
- Avian Influenza A (H5N1) Infection in HumansNew England Journal of Medicine, 2005